Oncolytic myxoma virus expressing fast p14 to treat hematological cancer
AssigneeArizona Board of Regents, a body Corporate of the State of Arizona, Acting for and
InventorsDouglas Grant McFADDEN, Roy DUNCAN, Mohammed Masmudur RAHMAN, Nancy VILLA, Ana LEMOS DE MATOS, Laura BELMONT
Life of this patent
Estimating the term…
Abstract
Provided herein are methods for inhibiting and/or treating a hematological cancer in a subject in need thereof using a myxoma virus that expresses one or more immunomodulatory transgenes, which includes FAST p14.
Claims24
A recombinant myxoma virus, comprising a heterologous immunomodulatory gene, wherein the heterologous immunomodulatory gene comprises a nucleic acid encoding p14 FAST.
(canceled)
A recombinant myxoma virus expression vector comprising a recombinant nucleic acid, wherein the recombinant nucleic acid comprises a heterologous immunomodulatory gene, and wherein the heterologous immunomodulatory gene comprises a nucleic acid encoding p14 FAST.
A method of inhibiting and/or treating a cancer in a subject in need thereof, comprising:
- administering to the subject a composition comprising a recombinant myxoma virus, wherein the recombinant myxoma virus comprises a heterologous immunomodulatory gene, and wherein the heterologous immunomodulatory gene comprises a nucleic acid encoding p14 FAST.
(canceled)
-23. (canceled)
26-32. (canceled)
Dependencies are inferred from the claim text.